BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

1 Customer Review

  • Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal NYfZbmhiU2mwYYPlJIF{e2G7 MV3pcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR|UxKD1iMUPuUUk> M3PsU|E6Pzd6MEK0
IGF-Sal M3TyfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVPJR|UxRTdibl2= NF;HeZIyQTd5OECyOC=>
CCRF-CEM (ALL) NID0bWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUP+OUDPxE1? M2W4[2ROW09? NVW3cJk3UUN3ME2xMlI{QSEQvF2= NEHCXmwyQTl7NkK3Ni=>
PC3 M1GzeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmH5glUh|ryP NFnm[pRFVVOR MmjOTWM2OD1yLkm2OUDPxE1? M{S5R|E6QTl4Mkey
JD NIriWVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXH+OUDPxE1? M2\C[WROW09? MYrJR|UxRTBwM{mxJO69VQ>? MXGxPVk6PjJ5Mh?=
DU145 MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUfiSJB2hjVizszN NGTOeG9FVVOR M3;WfWlEPTB;MT60OlUh|ryP NHPJOokyQTl7NkK3Ni=>
KAG NInycYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{HrVp42KM7:TR?= MY\EUXNQ NVf2OmNYUUN3ME2xMlY3PSEQvF2= MVixPVk6PjJ5Mh?=
K-562 (CML) NV3YZY5yT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXn+OUDPxE1? NVj6bml[TE2VTx?= M3;QdGlEPTB;Mj6zNFIh|ryP M{P3fVE6QTl4Mkey
B6-P210 (Murine ALL) MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEfYXpZ,PSEQvF2= M3LVTGROW09? NHuxU41KSzVyPUGuNlk{KM7:TR?= MVixPVk6PjJ5Mh?=
LN CAP-FGC M3XrUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnLpglUh|ryP Mn62SG1UVw>? NGnGXVFKSzVyPUGuOFM1KM7:TR?= Mm\pNVk6QTZ{N{K=
VW NXf3UXN6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHja[VF,PSEQvF2= MmrxSG1UVw>? NYnDWGozUUN3ME2wMlAyQSEQvF2= NHH6eIkyQTl7NkK3Ni=>
MV411 (B Myelomonocytic) M4\FOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3\LR542KM7:TR?= MV3EUXNQ NHrC[Y5KSzVyPUCuN|Mh|ryP MU[xPVk6PjJ5Mh?=
MDA-PCa-2b M1X6fWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmT5glUh|ryP MV;EUXNQ NFTlblFKSzVyPUCuNFk5KM7:TR?= MXuxPVk6PjJ5Mh?=
LG MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVfWUINNhjVizszN NH:1b45FVVOR MVjJR|UxRTBwMEO4JO69VQ>? MmHUNVk6QTZ{N{K=
RS411 (B cell precursor-ALL) MoXCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX\ublc1hjVizszN NHHUdnBFVVOR NHW2eHpKSzVyPUCuNVAzKM7:TR?= NXL5XlJVOTl7OU[yO|I>
22-r-1 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVy2VYhnhjVizszN MkK5SG1UVw>? MkL2TWM2OD1yLkG3OUDPxE1? MYSxPVk6PjJ5Mh?=
5838 MnLPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH3XfWV,PSEQvF2= M{P4RmROW09? NE\l[ZhKSzVyPUCuNFM1KM7:TR?= NX\KTnRkOTl7OU[yO|I>
P388 (Murine) M2[3NGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXLhR|N6hjVizszN Mlf2SG1UVw>? NWHNb4VDUUN3ME20MlI4KM7:TR?= MYCxPVk6PjJ5Mh?=
A2780/S NIfsTFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3ixWJ42KM7:TR?= M2Hm[mROW09? M4j5cmlEPTB;MD6xNlIh|ryP MXexPVk6PjJ5Mh?=
RDES NYDE[49lT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEPxS4J,PSEQvF2= MlLaSG1UVw>? MWLJR|UxRTBwMEGyJO69VQ>? NXex[XdTOTl7OU[yO|I>
B6-T315I (Murine B-ALL) MkXUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFXyd5R,PSEQvF2= NXy4Opc{TE2VTx?= NHLnVVNKSzVyPUKuPFMh|ryP MX:xPVk6PjJ5Mh?=
TOV 112D NYXn[|lKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHzzTpJ,PSEQvF2= NELENZFFVVOR Ml7qTWM2OD1{LkG0OkDPxE1? M3nXOVE6QTl4Mkey
TC32 NXPtOYhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUjEXVRXhjVizszN NHnxcXNFVVOR MnvUTWM2OD1yLkCwPEDPxE1? NVnTSXExOTl7OU[yO|I>
HL60 (acute myelocytic) MkfhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MknzglUh|ryP NHGzZ29FVVOR MlPhTWM2OD1yLkGyJO69VQ>? M4LXc|E6QTl4Mkey
TOV 21G M37uVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGDh[lh,PSEQvF2= MnToSG1UVw>? MmnUTWM2OD12LkK3PUDPxE1? M1ztclE6QTl4Mkey
TC71 M134emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVT+OUDPxE1? MoLRSG1UVw>? NGrvZ5BKSzVyPUCuNFE1KM7:TR?= MnTpNVk6QTZ{N{K=
HPN-ALL (T-cell) NXPtTHdPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NE\lbZJ,PSEQvF2= NHm4WYpFVVOR MYjJR|UxRTBwNUKg{txO M37nPFE6QTl4Mkey
A2780R MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnW4glUh|ryP NE\z[m5FVVOR MV7JR|UxRTFwNU[0JO69VQ>? MlnMNVk6QTZ{N{K=
Rh1 NVL4O2tDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkfzglUh|ryP NYDERZBITE2VTx?= NYPHbZhzUUN3ME2wMlAzPyEQvF2= MXGxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid) M4jlXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEHvbIN,PSEQvF2= MX7EUXNQ NWHBeZdTUUN3ME2wMlE3KM7:TR?= NG\2ZZAyQTl7NkK3Ni=>
sk-ov-3 M3nKS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXf+OUDPxE1? M1fZRWROW09? Ml3CTWM2OD13LkGg{txO NH\aNnEyQTl7NkK3Ni=>
ME MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoOwglUh|ryP MW\EUXNQ Mn;6TWM2OD1yLkCxOUDPxE1? Mn3SNVk6QTZ{N{K=
L1210 (Murine lymphocytic) NInuVFNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYXrS4Z5hjVizszN NFX6b4tFVVOR M2\xVWlEPTB;Mj6zPUDPxE1? NHrXZ5QyQTl7NkK3Ni=>
sw-626 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnj2glUh|ryP MVPEUXNQ MYjJR|UxRTJwM{C2JO69VQ>? MmHhNVk6QTZ{N{K=
CTR NFrEVWdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXG4WHRqhjVizszN MmTHSG1UVw>? NEnCdo5KSzVyPUCuNlU{KM7:TR?= MkLvNVk6QTZ{N{K=
ML2 (Myelomonocytic) Mme0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NInkfYJ,PSEQvF2= NFLJXmZFVVOR NGTpflVKSzVyPUCuNFkh|ryP MlqxNVk6QTZ{N{K=
ovcar-3 NXj3[XhrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXf+OUDPxE1? M2frdGROW09? MmezTWM2OD13IN88US=> M4DmOVE6QTl4Mkey
Rh36 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYL+OUDPxE1? NFzGbGFFVVOR NXTZSW5WUUN3ME2xMlQ{OiEQvF2= MVGxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid) NGTUN|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVP+OUDPxE1? M4TjPGROW09? M2HkVGlEPTB;MD60NkDPxE1? NFTRfHcyQTl7NkK3Ni=>
ovcar-4 NUDORnVpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX7BSolZhjVizszN NF3SPG1FVVOR MWTJR|UxRTFizszN M3nDelE6QTl4Mkey
Rh41 M3LqOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWnONW57hjVizszN M4rESGROW09? MUnJR|UxRTBwMEC1JO69VQ>? Mnm1NVk6QTZ{N{K=
Mutz 2 (acute myeloid) NFqyc|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmjKglUh|ryP MU\EUXNQ NHuyN5pKSzVyPUGuNVUh|ryP M3HqV|E6QTl4Mkey
ovcar-5 NYm5b5ZET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXroSJBOhjVizszN MWrEUXNQ M{nESGlEPTB;MD6wOUDPxE1? M{jGV|E6QTl4Mkey
RD1 MoLvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUn+OUDPxE1? NGD4S4NFVVOR NGj1NYhKSzVyPUCuNFY5KM7:TR?= NUfxPHFTOTl7OU[yO|I>
OCI-AML 2 (acute myeloid) NVLROoJFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnW3glUh|ryP NVv3cGM2TE2VTx?= MlmxTWM2OD1|LkOzJO69VQ>? MmnBNVk6QTZ{N{K=
786-O Mni1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHe4Wpd,PSEQvF2= MoPrSG1UVw>? M1\UbmlEPTB;MT62OFch|ryP Mm\ONVk6QTZ{N{K=
A673 NHPiU2VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2L4cZ42KM7:TR?= NHPQb5JFVVOR MojoTWM2OD1yLkSwPEDPxE1? NYi0cmwxOTl7OU[yO|I>
TALL-1 (T-cell) MkXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2mxS542KM7:TR?= MoPKSG1UVw>? MVfJR|UxRTFwMkig{txO NUHFTGhvOTl7OU[yO|I>
151-B MmfOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVzmOXR5hjVizszN NV3IT|NjTE2VTx?= M1HLUWlEPTB;Mj62O{DPxE1? NEP0SHUyQTl7NkK3Ni=>
PFSK-1 MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NF61dFB,PSEQvF2= MYLEUXNQ M2HXbWlEPTB;MD6xN|Ih|ryP MmLCNVk6QTZ{N{K=
THP-1 M1HU[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NV;aW5BqhjVizszN MUXEUXNQ MmPNTWM2OD14LkW4JO69VQ>? NG\2bGEyQTl7NkK3Ni=>
HEK293 NGXjSXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NITM[mh,PSEQvF2= MoG2SG1UVw>? MXfJR|UxRTBwOUG1JO69VQ>? NVfpUG9iOTl7OU[yO|I>
DAOY MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVf+OUDPxE1? MU\EUXNQ MmHxTWM2OD1zLkm3PUDPxE1? M3;NTlE6QTl4Mkey
SET2 NH3IUXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXrN[HdLhjVizszN NXziNpQyTE2VTx?= NWPw[Xl3UUN3ME2wMlI6QCEQvF2= M321RlE6QTl4Mkey
HTB-46 NHHBWpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NELaU4x,PSEQvF2= MU\EUXNQ M3TuTWlEPTB;NT6yOUDPxE1? MnTCNVk6QTZ{N{K=
SK-NAS NX[wPGhwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUX+OUDPxE1? M2DRO2ROW09? M2q5cGlEPTB;MD60PVch|ryP MUexPVk6PjJ5Mh?=
CTLL2 M13NTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2nIdp42KM7:TR?= MnLkSG1UVw>? M3XocWlEPTB-MT6wNEDPxE1? M1m0NlE6QTl4Mkey
HTB-47 NVXRcYZJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVnaOpZuhjVizszN M171ZmROW09? MlroTWM2OD1{LkC1OkDPxE1? MWKxPVk6PjJ5Mh?=
LAN-1 MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVX+OUDPxE1? MYnEUXNQ M1jvPGlEPTB;MD6wOEDPxE1? MWixPVk6PjJ5Mh?=
ST486 MoHrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYn1eWU5hjVizszN NIXHbVZFVVOR NVvWeYRSUUN3ME2xMlE6KM7:TR?= M2LhPFE6QTl4Mkey
HS766T NHznbnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXf+OUDPxE1? NHHzdZJFVVOR NHm2VVdKSzVyPUKuNFAyKM7:TR?= M2fqPVE6QTl4Mkey
IMR-32 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NG\Y[2p,PSEQvF2= MULEUXNQ MWrJR|UxRTBwMk[xJO69VQ>? NGq1XWQyQTl7NkK3Ni=>
Daudi (Burkitt's) MlztS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIO0cHR,PSEQvF2= NFu4UIZFVVOR NGHz[pdKSzVyPUKuOlM4KM7:TR?= M3[yRVE6QTl4Mkey
Aspc-1 NYnQSGk3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfwXY8zhjVizszN M4TvTWROW09? M4rWZmlEPTB;MD6zO|kh|ryP NFXke5gyQTl7NkK3Ni=>
SK-NSH NX7WZZRuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWD+OUDPxE1? MXnEUXNQ NGXISYdKSzVyPUCuNVM6KM7:TR?= NYKwSZRVOTl7OU[yO|I>
MEC-1 (Chronic B cell) NFHRNHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVvkbpdHhjVizszN MULEUXNQ M{LNV2lEPTB;Mj62N|ch|ryP MnjrNVk6QTZ{N{K=
Capan-2 NIPEb4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NV61Tmk{hjVizszN M1jJfWROW09? MofOTWM2OD1zLke3OEDPxE1? MlLTNVk6QTZ{N{K=
SHSY5Y M3OzNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnrTglUh|ryP MYrEUXNQ NV3ncnI3UUN3ME2wMlExPiEQvF2= NW\4SVVOOTl7OU[yO|I>
U937 (Histioocytic) M1K1XWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{nVPJ42KM7:TR?= MVvEUXNQ NHr0PIFKSzVyPkWuNFAh|ryP MYmxPVk6PjJ5Mh?=
Bxpc-1 M{Xwd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH\oeZB,PSEQvF2= Moe5SG1UVw>? NFr3cnBKSzVyPUGuPVI1KM7:TR?= M4jT[FE6QTl4Mkey
Bxpc-3 M4i4dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGLmTG9,PSEQvF2= MV7EUXNQ MoCxTWM2OD53LkCwJO69VQ>? M3zaZlE6QTl4Mkey
HTB-92 M3zTd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVTB[YxOhjVizszN NEixZ3JFVVOR MnHTTWM2OD1zLkCyJO69VQ>? Ml3SNVk6QTZ{N{K=
OCI-LY10 (B-cell) NWe1Z294T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4P0dp42KM7:TR?= MlmySG1UVw>? NYHQNIZoUUN3ME2wMlQ2KM7:TR?= NFXkRnEyQTl7NkK3Ni=>
PANC-1 NG\hfI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYTLW4RJhjVizszN MlX4SG1UVw>? NHfFc2xKSzVyPkWuNFAh|ryP NIL3O20yQTl7NkK3Ni=>
To184.T MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MljlglUh|ryP NGm1XGRFVVOR NGnwRnRKSzVyPUCuOFY6KM7:TR?= NGXMXVUyQTl7NkK3Ni=>
OCI-LY19 (B-cell) Mn3VS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUH+OUDPxE1? M4XLW2ROW09? NHXSSWZKSzVyPUCuOEDPxE1? MnHINVk6QTZ{N{K=
PANC-1 BM M3rhXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml7kglUh|ryP NVPR[W5nTE2VTx?= MmD3TWM2OD53LkCwJO69VQ>? M4HTclE6QTl4Mkey
SA-4 NVK3[IFkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVfOOVRMhjVizszN NGPISXVFVVOR MmP6TWM2OD1zLkOwNUDPxE1? MmjwNVk6QTZ{N{K=
RPMI 8226 NWTD[lN5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYKxVmpRhjVizszN MYrEUXNQ MkC0TWM2OD1zLkK5N{DPxE1? NVPVPI5uOTl7OU[yO|I>
HPAF-II MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIjBPIh,PSEQvF2= MoXrSG1UVw>? NHHrbYRKSzVyPUCuOlQ1KM7:TR?= MlfnNVk6QTZ{N{K=
SHP-77 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnvQglUh|ryP NGjsRmZFVVOR NH;iNlNKSzVyPUGuPFg5KM7:TR?= Mlu3NVk6QTZ{N{K=
U266 B1 MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXfsR2FQhjVizszN MXLEUXNQ MUfJR|UxRTFwNk[5JO69VQ>? MV6xPVk6PjJ5Mh?=
Hs700t M{LYWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1PrWJ42KM7:TR?= NX\0NY1NTE2VTx?= NVnDfXpFUUN3ME2wMlI{OSEQvF2= MUexPVk6PjJ5Mh?=
NCI-446 NUP1e2EyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVL4fXYzhjVizszN NIjLXZlFVVOR NH\lZZhKSzVyPUGuNVU1KM7:TR?= NFnsVYEyQTl7NkK3Ni=>
H929 M33ENWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmTKglUh|ryP MYTEUXNQ MUfJR|UxRTBwMEG0JO69VQ>? M3v4fFE6QTl4Mkey
PL45 NYG1fVAyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4XyRp42KM7:TR?= NFL3[YZFVVOR MlTkTWM2OD1{LkK1OUDPxE1? Mnr4NVk6QTZ{N{K=
NCI-H383 NYfRVmVpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVnUfFlbhjVizszN NX63XVc1TE2VTx?= NH3uUZVKSzVyPkWuNFAh|ryP Mm\SNVk6QTZ{N{K=
JJN3 MkDiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4jtZp42KM7:TR?= NXr6bnRjTE2VTx?= MXLJR|UxRTJwNEOzJO69VQ>? NFvPTVMyQTl7NkK3Ni=>
SU.86.86 NVTkO21VT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWH+OUDPxE1? NX;sS246TE2VTx?= MmnpTWM2OD1{Lk[3NkDPxE1? NHi1cVEyQTl7NkK3Ni=>
H1299 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVjpO|JyhjVizszN MV\EUXNQ NV3ucllFUUN3ME61MlAxKM7:TR?= MoO1NVk6QTZ{N{K=
MDA-MB-468 NIDibW5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYXsWXB5hjVizszN NWn6TJU1TE2VTx?= MoXNTWM2OD1yLkWwOEDPxE1? M4Phd|E6QTl4Mkey
SW1990 MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDGWnJqhjVizszN MWLEUXNQ MWXJR|UxRTBwOEK2JO69VQ>? NX\xVYVCOTl7OU[yO|I>
Calu-6 M{jyfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWj0bHRrhjVizszN MkDQSG1UVw>? NF7LZVRKSzVyPkWuNFAh|ryP MkPlNVk6QTZ{N{K=
MDA-MB-231 NWft[mllT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEDOVJh,PSEQvF2= NIfE[IhFVVOR Mnf1TWM2OD1zLk[0PEDPxE1? NWrJNIt4OTl7OU[yO|I>
SW-684 M1XUN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVz+OUDPxE1? NXvPcFc2TE2VTx?= NV;4dZl5UUN3ME61MlAxKM7:TR?= M2S5SlE6QTl4Mkey
H209 Ml;CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXH+OUDPxE1? NHrmb4lFVVOR NXr3TVFkUUN3ME2xMlE6OyEQvF2= M1v3[lE6QTl4Mkey
MDA-MB-231T MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDtPJZthjVizszN NHXqV|JFVVOR NFTPR4ZKSzVyPkWuNFAh|ryP MXWxPVk6PjJ5Mh?=
HT1080/S MnHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkTlglUh|ryP NInMeHhFVVOR MXvJR|UxRTBwNUOxJO69VQ>? NWPyOVkzOTl7OU[yO|I>
H526 0.044 M{DHXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{HKNJ42KM7:TR?= MV7EUXNQ NHru[m1KSzVyPUCuNFQ1KM7:TR?= NXPqWJZ6OTl7OU[yO|I>
DU4475 2.431 NGCzboZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUP+OUDPxE1? M3ThPWROW09? MlPrTWM2OD1{LkSzNUDPxE1? NYLjbGQyOTl7OU[yO|I>
HCT116 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYLHeWpChjVizszN MULEUXNQ NF;t[nhKSzVyPUCuPFUzKM7:TR?= M2fvU|E6QTl4Mkey
M109 MnWzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGPSWnp,PSEQvF2= MkLWSG1UVw>? MYHJR|UxRTFwMEW1JO69VQ>? MYixPVk6PjJ5Mh?=
BT549 M1vwNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2fmep42KM7:TR?= MmDHSG1UVw>? Mlz3TWM2OD1zLk[0OUDPxE1? NXjORmdIOTl7OU[yO|I>
HCT116/VM46 MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGLzT4Z,PSEQvF2= MnnvSG1UVw>? NWrkUlYzUUN3ME2xMlcxOiEQvF2= M3XnTVE6QTl4Mkey
H460 NFjTW4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{DYXp42KM7:TR?= NX;EcFM2TE2VTx?= MUTJR|UxRTBwN{m1JO69VQ>? NEnKO4wyQTl7NkK3Ni=>
MCF-7 MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFzHbJZ,PSEQvF2= M3v6NGROW09? M4DyOmlEPTB;MD6wNVYh|ryP M{DHSFE6QTl4Mkey
GEO NEWwOWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIHGO2R,PSEQvF2= NHf2NXJFVVOR NWjhSm9{UUN3ME2wMlM2PiEQvF2= MUexPVk6PjJ5Mh?=
H441 0.646 M3HvVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWfGelRlhjVizszN MYTEUXNQ M1XQTGlEPTB;MD62OFYh|ryP NGPSNHMyQTl7NkK3Ni=>
MCF-7-807R NUHWfIN5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUnubpNMhjVizszN NFm0fJhFVVOR M3rhZ2lEPTB;MD60PUDPxE1? NFrPWWsyQTl7NkK3Ni=>
Colo205 MoTXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH65bmV,PSEQvF2= M3vC[WROW09? MWHJR|UxRTBwMUC0JO69VQ>? M3;SNFE6QTl4Mkey
H292 Mne0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWL4cW1qhjVizszN NGXCU5JFVVOR NYqwUo9yUUN3ME2wMlc5QCEQvF2= NIroVJkyQTl7NkK3Ni=>
BT474 (S) NYrieFVGT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHPLeo1,PSEQvF2= NUPHempWTE2VTx?= NFftdXBKSzVyPUKuOFA{KM7:TR?= NUjw[3RyOTl7OU[yO|I>
HT-29 NH7pNHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NW\ieW16hjVizszN M1:2SWROW09? NFf3b4ZKSzVyPUKuNVA{KM7:TR?= M1fHPVE6QTl4Mkey
A549 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnHJglUh|ryP MnLuSG1UVw>? NFXYR3RKSzVyPUCuOlc2KM7:TR?= MXSxPVk6PjJ5Mh?=
BT474-M1 M1HtZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVL+OUDPxE1? MnPJSG1UVw>? M1zNc2lEPTB;Mj6zOlUh|ryP MYCxPVk6PjJ5Mh?=
SW480 M{DZcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXn+OUDPxE1? NFj4NIJFVVOR MmDGTWM2OD53LkCwJO69VQ>? MoTqNVk6QTZ{N{K=
L2987 NED3Um1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mn\DglUh|ryP NVz5dot{TE2VTx?= MWTJR|UxRTBwNESyJO69VQ>? NUjSW2t1OTl7OU[yO|I>
AU565 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{n1SJ42KM7:TR?= NHfEdYdFVVOR MYPJR|UxRTRwOUeg{txO MU[xPVk6PjJ5Mh?=
SW403 MmLWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV;+OUDPxE1? MoD6SG1UVw>? NFvuWJJKSzVyPUCuNlIh|ryP NXXTUIkzOTl7OU[yO|I>
H1437 MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmfYglUh|ryP Ml3RSG1UVw>? MW\JR|UxRTBwNUKzJO69VQ>? NX3EWmNTOTl7OU[yO|I>
BT-20 MmXCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmL0glUh|ryP NXz0V4lXTE2VTx?= M{jiRmlEPTB;Mz61OlIh|ryP MX6xPVk6PjJ5Mh?=
Colo320HSR MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1vXR542KM7:TR?= NEfLO4pFVVOR NV;pbWplUUN3ME2wMlAyOSEQvF2= MVWxPVk6PjJ5Mh?=
H2087 M3TOOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUn+OUDPxE1? NXG1UXR3TE2VTx?= MYHJR|UxRjFwMECg{txO M{DtNVE6QTl4Mkey
HCC1419 MkPPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml7iglUh|ryP NIrtV4hFVVOR NH\6c5FKSzVyPUKuOVE4KM7:TR?= MWGxPVk6PjJ5Mh?=
WiDr M2XKVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVHNb2E2hjVizszN MVjEUXNQ MljjTWM2OD1yLkC3OkDPxE1? MmX2NVk6QTZ{N{K=
H661 0.573 NInWSHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXnpTlV1hjVizszN M2PUZWROW09? MWjJR|UxRTBwNUezJO69VQ>? M4jCN|E6QTl4Mkey
HCC-38 MmrOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX3+OUDPxE1? Ml7CSG1UVw>? MULJR|UxRjVwMECg{txO NH;MdJkyQTl7NkK3Ni=>
LS174T Moq4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmGxglUh|ryP M{e5fWROW09? MoPlTWM2OD1yLkWzOUDPxE1? NFrWUXoyQTl7NkK3Ni=>
H211 MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NI\YbJl,PSEQvF2= NWPDPXBETE2VTx?= M3uxTmlEPTB;MD63N|Mh|ryP NEX3O3gyQTl7NkK3Ni=>
HCC70 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkXFglUh|ryP MXzEUXNQ Mn7VTWM2OD1zLkW1JO69VQ>? NYX4[WhqOTl7OU[yO|I>
SW116 MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWPsR3JrhjVizszN MXzEUXNQ NGDJTnZKSzVyPUCuNFY4KM7:TR?= NVqy[5VmOTl7OU[yO|I>
H513 NIXE[WNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3Pob542KM7:TR?= NVrOZpZ2TE2VTx?= M{jiRWlEPTB;ND60OFgh|ryP NH7mbpgyQTl7NkK3Ni=>
MDA-MB-157 M4Tkbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIrzfZJ,PSEQvF2= NW\IWo94TE2VTx?= M{fKNWlEPTB;MD6wN|Yh|ryP NHmxU3EyQTl7NkK3Ni=>
H2052 MlS1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mm[wglUh|ryP M1fh[WROW09? MkXZTWM2OD1zLkC1JO69VQ>? MofTNVk6QTZ{N{K=
MDA-MB-415 NULL[2JPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXP+OUDPxE1? M3XNUWROW09? M1jDbmlEPTB-NT6wNEDPxE1? M2jsNFE6QTl4Mkey
DLD-1 NHfEephIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoHVglUh|ryP NH7YdmlFVVOR NUHhZW1UUUN3ME2wMlkxQSEQvF2= Mme3NVk6QTZ{N{K=
H2595 NFK0WotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2i4dZ42KM7:TR?= NI\NXZVFVVOR NWfGeHFHUUN3ME20MlQ4PSEQvF2= MVSxPVk6PjJ5Mh?=
MDA-MB-435S MmrmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{C5Z542KM7:TR?= NVPsT2pbTE2VTx?= MnvhTWM2OD1zLki2PUDPxE1? NVXRRZd{OTl7OU[yO|I>
HCT15 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYLx[2tLhjVizszN M1Trd2ROW09? MYTJR|UxRjFwMECg{txO NWDpenZUOTl7OU[yO|I>
SK-Hep1 NUDGdoVkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYDpO5BXhjVizszN M4LlUWROW09? MoLITWM2OD1yLkG0OkDPxE1? MYWxPVk6PjJ5Mh?=
MDA-MB-436 NHm5RVZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnrrglUh|ryP MoXOSG1UVw>? NH:x[4lKSzVyPUWuOVAzKM7:TR?= NVfEeYNHOTl7OU[yO|I>
KM12C NXLtTldJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUn+OUDPxE1? MX3EUXNQ MW\JR|UxRTBwMEW0JO69VQ>? M2jCOlE6QTl4Mkey
HEPG2 NEnEUXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX;+OUDPxE1? M2nmOWROW09? Mk\xTWM2OD1yLkCyOUDPxE1? MnXHNVk6QTZ{N{K=
MDA-MB-453 NUjRPXJVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWT+OUDPxE1? MVfEUXNQ MnjDTWM2OD1zLki2PUDPxE1? NHjyNVAyQTl7NkK3Ni=>
KM12SM MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{HUVJ42KM7:TR?= M3fwfGROW09? NF[zcIpKSzVyPUCuNFU6KM7:TR?= NULte25COTl7OU[yO|I>
1483 NV;IVYt6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnrKglUh|ryP MmO3SG1UVw>? NUe1ZXhTUUN3ME2yMlE6KM7:TR?= MmLNNVk6QTZ{N{K=
Hs578t M2Tw[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGL5N4R,PSEQvF2= MV\EUXNQ MUTJR|UxRTFwMki3JO69VQ>? NWDXNmhjOTl7OU[yO|I>
LS180 Mn3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3K2cp42KM7:TR?= MoPHSG1UVw>? MXrJR|UxRTBwNkm2JO69VQ>? NITnZXoyQTl7NkK3Ni=>
FaDu NUnSWlJxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M33YPJ42KM7:TR?= NITp[HFFVVOR NIPIT2NKSzVyPUGuNlch|ryP NHPzToIyQTl7NkK3Ni=>
ZR-75-1 NIT5fJBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmXtglUh|ryP NGS4T|lFVVOR NVu5SVBIUUN3ME2yMlA5PCEQvF2= NVTQRmh1OTl7OU[yO|I>
LS513 NGrMelVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlzJglUh|ryP M130ZWROW09? Mk\lTWM2OD1yLkGzOUDPxE1? NXvKbVg2OTl7OU[yO|I>
Detroit.562 MlTyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFT3[ZJ,PSEQvF2= NWfCXFhGTE2VTx?= MWrJR|UxRTFwMUSg{txO NFLQd4cyQTl7NkK3Ni=>
ZR-75-30 Mn\1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NV;wdWxqhjVizszN MW\EUXNQ MV3JR|UxRjVwMECg{txO MlnvNVk6QTZ{N{K=
RKO-PM Moj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NY\4SpVmhjVizszN NETFe|BFVVOR NYrQV5dDUUN3ME2wMlI{OiEQvF2= NXzOV5c6OTl7OU[yO|I>
Cal.27 MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1TkUZ42KM7:TR?= NWG5[|lCTE2VTx?= M1;w[GlEPTB;MjFOwG0> M1;ze|E6QTl4Mkey
KPL4 M2rQ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWjtUlVQhjVizszN M{TuS2ROW09? MUXJR|UxRTFwMkWyJO69VQ>? NITZZoIyQTl7NkK3Ni=>
PKO-RM13 MlLuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUPBdWlEhjVizszN MlrjSG1UVw>? MXjJR|UxRTBwNEK1JO69VQ>? MmjKNVk6QTZ{N{K=
HS.53.T MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXj+OUDPxE1? MkP6SG1UVw>? MVTJR|UxRTBwN{mg{txO MnTaNVk6QTZ{N{K=
EMT6 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIDzU3V,PSEQvF2= NWi0Tod7TE2VTx?= NIrSV2FKSzVyPUCuPFA3KM7:TR?= MnntNVk6QTZ{N{K=
SNU-C1 MmTOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NILy[3J,PSEQvF2= MnfTSG1UVw>? NWnCWlA4UUN3ME2wMlAxPyEQvF2= M{nHTFE6QTl4Mkey
SQCCY1 MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2DRZZ42KM7:TR?= MoP3SG1UVw>? MYnJR|UxRTBwN{mg{txO NFXGXYoyQTl7NkK3Ni=>
SW480 M1y1dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mkj4glUh|ryP MmDmSG1UVw>? M{fHWWlEPTB;MD6wN|ch|ryP MoLRNVk6QTZ{N{K=
SCC9 NYHSNo1jT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXXWfFdohjVizszN MWPEUXNQ NVjx[Gt3UUN3ME2wMlc2KM7:TR?= M{ixPFE6QTl4Mkey
SK-LMS-1 NInIfmNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1nUZZ42KM7:TR?= MkjUSG1UVw>? NXr5eFgxUUN3ME2wMlY5PyEQvF2= NHnafGoyQTl7NkK3Ni=>
SCC25 MmroS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NInDOHV,PSEQvF2= MWPEUXNQ NHrwOG9KSzVyPUCuOlgh|ryP MkjiNVk6QTZ{N{K=
U87 MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4fnN542KM7:TR?= MmTtSG1UVw>? NGfYbJBKSzVyPUCuPVUh|ryP M{e2bFE6QTl4Mkey
SCC15 M3rDVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIrweHN,PSEQvF2= MX\EUXNQ M2\oT2lEPTB;MD62O{DPxE1? MV6xPVk6PjJ5Mh?=
T98G M3v0S2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX;+OUDPxE1? MlLKSG1UVw>? MUnJR|UxRTFwMkG4JO69VQ>? NWS4UYNWOTl7OU[yO|I>
SCC4 NFXjPY9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3S3UZ42KM7:TR?= NYjpVoxoTE2VTx?= MVLJR|UxRTBwNkOg{txO NFjyVo4yQTl7NkK3Ni=>
U118 NIPJUJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MofCglUh|ryP NFXUUG9FVVOR NFTFbINKSzVyPUGuOlE5KM7:TR?= MW[xPVk6PjJ5Mh?=
TU167 Ml\mS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYP+OUDPxE1? NV\XbFVxTE2VTx?= NIrIe2dKSzVyPUSuOVIh|ryP MmfrNVk6QTZ{N{K=
NCI-H727 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3ezV54yOOLCit88US=> NEL6dJpFVVOR NXzJfGtmUUN3ME20Nlghdk1? MlXTNlA{QDV5NEe=
NCI-H720 M4XwT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUjmV5BthjFy4pEK{txO NV;OfmdQTE2VTx?= MXrJR|UxRTJwODFOwG0> NI\KW|gzODN6NUe0Oy=>
NCI-H835 MmTTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4Pq[Z4yOOLCit88US=> M{jKSmROW09? NHT6PZhKSzVyPUGg{txO MWKyNFM5PTd2Nx?=
NCI-H727 NXzRXnp4U2mwYYPlJIF{e2G7 MWL+NVDjiIsQvF2= M2PvcmROW09? NUTUR2xucW6qaXLpeJMh[2:wc4TpeJV1cX[nIFnHSlFTKGG3dH;wbI9{eGixconsZZRqd25? NV63UplKOjB|OEW3OFc>
RD MmnXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3\aRp4yOOLCit88US=> NXrwfHpvUUN3ME2xMlEzKML3TR?= NUnIdlY2OjF{OUi3OFU>
Rh41 NILxUZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUL+NVDjiIsQvF2= M{HPSGlEPTB;MD6wO{DDvU1? MWSyNVI6QDd2NR?=
Rh18 NUnObFhwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoPyglEx6oDMzszN NISzU5FKSzVyPUSuPVYhyrWP MojGNlEzQTh5NEW=
Rh30 NHXYU|FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFe2UJp,OTEkgJtOwG0> NWT2R251UUN3ME2wMlE6KML3TR?= M3PrWFIyOjl6N{S1
BT-12 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{nZRZ4yOOLCit88US=> M4rRZ2lEPTB;MD63PEDDvU1? Mk\QNlEzQTh5NEW=
CHLA-266 Mk\OS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHLDSFB,OTEkgJtOwG0> MoDtTWM2OD1yLki5JOK2VQ>? M2XZTFIyOjl6N{S1
TC-71 NWnpZVk5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1nEdJ4yOOLCit88US=> M1TacmlEPTB;MD6xNUDDvU1? NXPSSnlPOjF{OUi3OFU>
CHLA-9 NWHpdGMxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVP+NVDjiIsQvF2= MVLJR|UxRTBwMUKgxtVO NGnxd2wzOTJ7OEe0OS=>
CHLA-10 M3vuPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NI[zd4p,OTEkgJtOwG0> MWfJR|UxRTBwNkKgxtVO MknINlEzQTh5NEW=
CHLA-258 M4TnV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYD1O|FvhjFy4pEK{txO NWnwRo9UUUN3ME2wMlI4KML3TR?= NWDiNHppOjF{OUi3OFU>
GBM2 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGWycHd,OTEkgJtOwG0> MojvTWM2OD1zLkS3JOK2VQ>? M1nhflIyOjl6N{S1
NB-1643 MoflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUT+NVDjiIsQvF2= MlXjTWM2OD1yLkGyJOK2VQ>? M{LRTlIyOjl6N{S1
NB-EBc1 NH7YN2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUjuTlZShjFy4pEK{txO NHTVeWZKSzVyPUCuN|UhyrWP MofMNlEzQTh5NEW=
CHLA-90 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHLpXoR,OTEkgJtOwG0> MXrJR|UxRTBwN{egxtVO MWeyNVI6QDd2NR?=
CHLA-136 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Moj5glEx6oDMzszN NH7z[IpKSzVyPUCuOVIhyrWP MXSyNVI6QDd2NR?=
NALM-6 M13aWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYf+NVDjiIsQvF2= MWXJR|UxRTBwNEmgxtVO NHy5OXczOTJ7OEe0OS=>
COG-LL-317 M4Dnd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmfXglEx6oDMzszN NGTnO2ZKSzVyPUGuN|ghyrWP NWPqW5FkOjF{OUi3OFU>
RS4;11 MlL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHq1TFV,OTEkgJtOwG0> Mk\KTWM2OD1yLkO4JOK2VQ>? MXeyNVI6QDd2NR?=
MOLT-4 NWLiUYdtT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3TEfZ4yOOLCit88US=> M{LifWlEPTB;MD61N{DDvU1? M3rlSVIyOjl6N{S1
CCRF-CEM M1XKd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUH+NVDjiIsQvF2= M3r3d2lEPTB;MT6xN{DDvU1? NYHt[VFQOjF{OUi3OFU>
Kasumi-1 NHruflFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4HNcp4yOOLCit88US=> NHT3TWpKSzVyPUGuNkDDvU1? NVrXZ3JKOjF{OUi3OFU>
Karpas-299 NFriSFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlLjglEx6oDMzszN MlO4TWM2OD1zLk[0JOK2VQ>? MV2yNVI6QDd2NR?=
Ramos-RA1 MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYH+NVDjiIsQvF2= NXnIO3JOUUN3ME2xMlMyKML3TR?= NH7lbWozOTJ7OEe0OS=>
Rh30  NGPzcHBHfW6ldHnvckBie3OjeR?= M2[0XIlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= NFnySlIzPTl{NUO3PC=>
Rh41 MXvGeY5kfGmxbjDhd5NigQ>? NGG4boVqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= M{\DbFI2QTJ3M{e4
RD Ml3XSpVv[3Srb36gZZN{[Xl? M2qxO4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= NVr6eoJiOjV7MkWzO|g>
A549 NFeyZWlMcW6jc3WgZZN{[Xl? MkTmNE426oDMzszN M2nZPGROW09? NG\URYpqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>? Mnm0NlY6Ojh3N{i=
NCI-H358 M4GzfGtqdmG|ZTDhd5NigQ>? NYLkUGR4OC534pEK{txO NVLRPItUTE2VTx?= Ml:xbY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44> MWWyOlkzQDV5OB?=
A549 M{T6dmZ2dmO2aX;uJIF{e2G7 NYnRSJhOOC534pEK{txO NH\0XoFFVVOR MoLpZ4F2e2W|IHGgZ49v[3W{cnXueEBl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RiYX7kJGVTUw>? Mlv4NlY6Ojh3N{i=
NCI-H358 MX3GeY5kfGmxbjDhd5NigQ>? NWLZVYdjOC534pEK{txO NYfFdo9DTE2VTx?= NYL2fVdt[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?= MXGyOlkzQDV5OB?=
A549 MlO1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX\Gb3A3hjFy4pEK{txO NYTZPWp6TE2VTx?= NFv0XVZKSzVyPUCuO|Yh|ryP NGLiNpczPjl{OEW3PC=>
NCI-H358 M4jBXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUfMXWZlhjFy4pEK{txO NX2wXFFITE2VTx?= NYfYenBWUUN3ME2xMlA6KM7:TR?= NX\wPG1WOjZ7Mki1O|g>
A549 MWfBdI9xfG:|aYOgZZN{[Xl? M3PsblAvPeLCit88US=> NV;Zell4TE2VTx?= NXHjUmgycW6mdXPld{BCeG:ydH;zbZM> M4q1OlI3QTJ6NUe4
NCI-H358 MlPxRZBweHSxc3nzJIF{e2G7 NHXjbmUxNjYkgJtOwG0> NV3lWHJLTE2VTx?= MnjhbY5lfWOnczDBdI9xfG:|aYO= MW[yOlkzQDV5OB?=
A549 MXPGeY5kfGmxbjDhd5NigQ>? NHnybGExNjYkgJtOwG0> M2[4RmROW09? MWHy[YR2[2W|IIfveY5lKGOub4P1doU> NYPCVJZyOjZ7Mki1O|g>
NCI-H358 NIHPTVdHfW6ldHnvckBie3OjeR?= NXj2[|JSOC534pEK{txO MV3EUXNQ NX;4b5VZemWmdXPld{B4d3WwZDDjcI9{fXKn MW[yOlkzQDV5OB?=

... Click to View More Cell Line Experimental Data

In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
+ Expand
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID